A group of researchers at the institute recently received $1.6 million from the National Institutes of Health to develop anti-infective agents to neutralize methicillin-resistant Staphylococcus aureus, according to a news release. The project hopes to drive real-time microbial adaptations disadvantageous to pathogens for which antibiotics are all but useless.
“Antibiotic resistance is a predictable result of microbial survival instincts in the face of drugs that are designed to kill them…By fundamentally changing our approach, we are exploring totally new ways to tame the microbes and slow their resistance,” said Michael Yearman, PhD, one of the project’s researchers, in the release. “Our approach interferes with the adaptations MRSA uses to survive in the body. Enhancing the effectiveness of existing antibiotics and minimizing resistance by dangerous microbes like MRSA are public health priorities directly addressed by our research.”
More Articles on Infection Control & Clinical Quality:
MMR Vaccine Linked to Lower Hospital Admissions, Overall Infections
Mesh vs. Suture: Quality Outcomes in Primary Ventral Hernia Repairs
Antihypertensive Medications Increase Patient Risk of Falls
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
